Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

CRANBURY, NJ, USA I March 31, 2025 I Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Mounjaro, a weekly injection, targets GIP and GLP-1 hormones to enhance insulin release and appetite regulation, aiding ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay later under a partnership ...

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...

SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist ... once-daily oral semaglutide (maximal dose, 14 mg) or placebo, in addition to standard care.

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Dr. Rahul Baxi highlights that a new Rs 16,000-a-month weight-loss injection isn't a miracle solution without essential ...

Eli Lilly has priced Mounjaro at approximately Rs 4,375 ($50) for a single 5 mg injection, while the 2.5 mg variant costs Rs ...